Noah Medical, a San Carlos, CA-based medical robotics provider, raised $150M in Series B funding.
The round was led by Softbank Vision Fund and Prosperity7 Ventures, and included investments from from Tiger Global, and existing investors including Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, AME cloud ventures, as well as undisclosed investors.
The company intends to use the funds to meet demand for the Galaxy System, its integrated solution for navigated robotic bronchoscopy.
Led by Jian Zhang, PhD, founder and CEO, Noah Medical is building medical robotics. The Galaxy System is its first commercial robotic system that provides actionable clinical solutions through endoluminal technologies. The Galaxy system features TiLT+ technology with integrated tomosynthesis and augmented fluoroscopy, a single-use bronchoscope, and a small, compact footprint to enable improved procedural workflow across the lung biopsy market.
Already having received high marks from interventional pulmonologists who tested the system over the prior year, the company recently announced the platform received FDA clearance for commercial use in the United States and that it has initiated first-in-human trials at Macquarie University Hospital in Sydney, Australia.
FinSMEs
19/04/2023